MA52414A - Anticorps agonistes de pd-1 et leurs utilisations - Google Patents
Anticorps agonistes de pd-1 et leurs utilisationsInfo
- Publication number
- MA52414A MA52414A MA052414A MA52414A MA52414A MA 52414 A MA52414 A MA 52414A MA 052414 A MA052414 A MA 052414A MA 52414 A MA52414 A MA 52414A MA 52414 A MA52414 A MA 52414A
- Authority
- MA
- Morocco
- Prior art keywords
- agonist antibodies
- agonist
- antibodies
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637643P | 2018-03-02 | 2018-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52414A true MA52414A (fr) | 2021-01-06 |
Family
ID=65686121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052414A MA52414A (fr) | 2018-03-02 | 2019-02-22 | Anticorps agonistes de pd-1 et leurs utilisations |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10493148B2 (fr) |
| EP (1) | EP3759139A1 (fr) |
| JP (3) | JP7071521B2 (fr) |
| KR (2) | KR102536014B1 (fr) |
| CN (1) | CN111886253B (fr) |
| AR (1) | AR114127A1 (fr) |
| AU (2) | AU2019228474B2 (fr) |
| BR (1) | BR112020015983A2 (fr) |
| CA (1) | CA3092064C (fr) |
| CL (1) | CL2020002180A1 (fr) |
| CO (1) | CO2020010188A2 (fr) |
| CR (1) | CR20200375A (fr) |
| DO (1) | DOP2020000153A (fr) |
| EA (1) | EA202091809A1 (fr) |
| EC (1) | ECSP20053544A (fr) |
| IL (1) | IL276340A (fr) |
| JO (1) | JOP20200210A1 (fr) |
| MA (1) | MA52414A (fr) |
| MX (1) | MX2020009124A (fr) |
| PE (1) | PE20210045A1 (fr) |
| PH (1) | PH12020551463A1 (fr) |
| SA (1) | SA520420082B1 (fr) |
| SG (1) | SG11202008437WA (fr) |
| TW (1) | TWI708787B (fr) |
| WO (1) | WO2019168745A1 (fr) |
| ZA (1) | ZA202004601B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207393B2 (en) * | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| BR112019025574A2 (pt) | 2017-06-05 | 2020-06-23 | Janssen Biotech, Inc. | Anticorpos que se ligam especificamente ao pd-1 e métodos de uso |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| EP3768724A4 (fr) * | 2018-03-20 | 2022-04-13 | Wuxi Biologics Ireland Limited. | Nouveaux anticorps anti-pd-1 |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| EP4107187A4 (fr) | 2020-02-21 | 2024-07-03 | Pandion Operations Inc | Immunotolérance ciblée sur un tissu avec un effecteur cd39 |
| WO2021168192A2 (fr) * | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Immunotolérance ciblée sur un tissu avec des agonistes de pd-1 ou des mutéines d'il-2 |
| CN115485299A (zh) * | 2020-04-22 | 2022-12-16 | Igm生物科学股份有限公司 | Pd-1激动剂多聚结合分子 |
| US20230183347A1 (en) * | 2020-05-25 | 2023-06-15 | Foundation For Biomedical Research And Innovation At Kobe | PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease |
| AU2021280232A1 (en) | 2020-05-26 | 2022-12-15 | Boehringer Ingelheim International Gmbh | Anti-PD-1 antibodies |
| BR112023023400A2 (pt) | 2021-05-13 | 2024-01-23 | Foundation For Biomedical Res And Innovation At Kobe | Anticorpo agonista anti-pd-1 humano e composição farmacêutica compreendendo o anticorpo para tratamento ou prevenção de doenças inflamatórias |
| CN118284624A (zh) | 2021-11-19 | 2024-07-02 | 米罗生物有限公司 | Pd-1抗体及其用途 |
| WO2023200796A1 (fr) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Inhibition de cellules immunitaires par des engageurs de points de contrôle immunitaires |
| WO2024010861A2 (fr) * | 2022-07-06 | 2024-01-11 | Santa Ana Bio, Inc. | Méthodes et compositions pour le traitement de maladies auto-immunes, allergiques et inflammatoires |
| WO2024040206A2 (fr) * | 2022-08-19 | 2024-02-22 | Eli Lilly And Company | Anticorps agonistes de pd-1 et méthodes de traitement de maladies auto-immunes avec un anticorps agoniste de pd-1 |
| WO2024050421A2 (fr) * | 2022-08-30 | 2024-03-07 | Flagship Pioneering Innovations Vi, Llc | Molécules de liaison à l'antigène ciblant la protéine 1 de mort cellulaire programmée (pd-1) |
| WO2024092031A1 (fr) | 2022-10-25 | 2024-05-02 | Seismic Therapeutic, Inc. | Polypeptides fc d'igg variants et leurs utilisations |
| CN116284447A (zh) * | 2023-02-20 | 2023-06-23 | 苏州大学 | 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| EP3530736A3 (fr) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
| WO2009026472A1 (fr) | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Procédés pour induire une tolérance |
| JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Ｐｄ−１特異抗体およびその使用 |
| CA2736816C (fr) | 2008-09-12 | 2018-05-22 | Isis Innovation Limited | Anticorps specifiques de pd-1 et leurs utilisations |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP6094486B2 (ja) * | 2011-08-11 | 2017-03-15 | 小野薬品工業株式会社 | Ｐｄ−１アゴニストからなる自己免疫疾患治療剤 |
| CN105431449B (zh) | 2013-04-05 | 2021-08-24 | 港大科桥有限公司 | 新的pd1同种型及其用于加强免疫应答的用途 |
| JP6629321B2 (ja) * | 2014-08-05 | 2020-01-15 | マブクエスト エスエーＭａｂＱｕｅｓｔ ＳＡ | 免疫学的試薬 |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| CA3006224A1 (fr) | 2015-06-23 | 2016-12-29 | Memorial Sloan-Kettering Cancer Center | Nouveaux agents de modulation immunitaire pd -1 |
| BR112018006237A2 (pt) * | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| HUE059788T2 (hu) | 2015-10-02 | 2022-12-28 | Symphogen As | PD-1 elleni antitestek és készítmények |
| JP6654694B2 (ja) | 2015-10-02 | 2020-02-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ１抗体と使用方法 |
| KR20180085793A (ko) | 2015-12-02 | 2018-07-27 | 주식회사 에스티큐브 | 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법 |
| BR112019025574A2 (pt) | 2017-06-05 | 2020-06-23 | Janssen Biotech, Inc. | Anticorpos que se ligam especificamente ao pd-1 e métodos de uso |
-
2019
- 2019-02-18 TW TW108105310A patent/TWI708787B/zh active
- 2019-02-18 AR ARP190100406A patent/AR114127A1/es unknown
- 2019-02-22 CR CR20200375A patent/CR20200375A/es unknown
- 2019-02-22 KR KR1020207024945A patent/KR102536014B1/ko active IP Right Grant
- 2019-02-22 EP EP19709336.2A patent/EP3759139A1/fr active Pending
- 2019-02-22 PE PE2020001188A patent/PE20210045A1/es unknown
- 2019-02-22 AU AU2019228474A patent/AU2019228474B2/en active Active
- 2019-02-22 SG SG11202008437WA patent/SG11202008437WA/en unknown
- 2019-02-22 MX MX2020009124A patent/MX2020009124A/es unknown
- 2019-02-22 BR BR112020015983-2A patent/BR112020015983A2/pt unknown
- 2019-02-22 EA EA202091809A patent/EA202091809A1/ru unknown
- 2019-02-22 CN CN201980016779.7A patent/CN111886253B/zh active Active
- 2019-02-22 US US16/282,609 patent/US10493148B2/en active Active
- 2019-02-22 MA MA052414A patent/MA52414A/fr unknown
- 2019-02-22 JP JP2020545727A patent/JP7071521B2/ja active Active
- 2019-02-22 JO JOP/2020/0210A patent/JOP20200210A1/ar unknown
- 2019-02-22 WO PCT/US2019/019076 patent/WO2019168745A1/fr active Application Filing
- 2019-02-22 CA CA3092064A patent/CA3092064C/fr active Active
- 2019-02-22 KR KR1020237017035A patent/KR20230079458A/ko active Application Filing
-
2020
- 2020-07-24 ZA ZA2020/04601A patent/ZA202004601B/en unknown
- 2020-07-28 IL IL276340A patent/IL276340A/en unknown
- 2020-08-05 DO DO2020000153A patent/DOP2020000153A/es unknown
- 2020-08-19 CO CONC2020/0010188A patent/CO2020010188A2/es unknown
- 2020-08-24 CL CL2020002180A patent/CL2020002180A1/es unknown
- 2020-09-01 EC ECSENADI202053544A patent/ECSP20053544A/es unknown
- 2020-09-01 PH PH12020551463A patent/PH12020551463A1/en unknown
- 2020-09-02 SA SA520420082A patent/SA520420082B1/ar unknown
-
2022
- 2022-03-07 JP JP2022034413A patent/JP7259107B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061724A patent/JP2023093549A/ja active Pending
- 2023-07-10 AU AU2023204569A patent/AU2023204569A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
| MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
| MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
| MA53168A (fr) | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| MA52970A (fr) | Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA54539A (fr) | Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations | |
| MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
| MA52771A (fr) | Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations | |
| MA54540A (fr) | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations | |
| MA55627A (fr) | Agonistes de glp-1r et leurs utilisations | |
| MA54555A (fr) | Agonistes de glp-1r et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
| MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
| MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA49565A (fr) | Anticorps agonistes qui lient cd137 humain et leurs utilisations | |
| MA50397A (fr) | Anticorps anti-tau et leurs utilisations |